维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
Stock Code：1873.HK

NEWSLETTER Issue 10
Dec 2021 – Apr 2022

VIVA Company News

Viva Biotech Announced 2021 Annual Results: Group's Revenue Increased significantly by 201.9% YoY

On March 28, 2022, Viva Biotech Holdings (1873.HK) announced the annual results during the year ended December 31,2021. The revenue of the Group increased significantly by approximately 201.9% to RMB2,104.1 million from RMB697.0 million for the corresponding period last year. Gross profit increased substantially by approximately 113.5% to RMB651.0 million from RMB304.9 million for the corresponding period last year. The adjusted net profit of the Group increased from RMB252.3 million for the corresponding period last year to RMB352.5 million, representing a YoY increase of 39.7%.

In 2021, the revenue from CRO business increased significantly by approximately 68.7% to RMB740.4 million. The order backlog increased 58.9% to approximately RMB965.0 million. During the year, the Group made great efforts to strengthen the strategic integration of Langhua Pharmaceutical, intensifying the construction of CMC R&D centers for technology build-up, strengthening client outreach and business development activities for business growth, and accelerating production capacity building for production expansion. In terms of EFS business, the Company continued to extensively explore business opportunities around the globe. During the year, the Company had reviewed a total of over 979 projects globally and added 20 start-ups to the portfolio companies. And 14 of the portfolio companies completed a new round of financing, raising over US$360 million in total.

Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests

LANGHUA PHARMA

In January 2022, Langhua Pharmaceutical, a subsidiary of Viva Biotech, announced that it signed an agreement with the Medicines Patent Pool (MPP) to be authorized to produce raw ingredient of COVID-19 antiviral medication molnupiravir. The authorisation granted to Langhua Pharmaceutical by MPP represents a high affirmation and recognition in its process development and amplification of APIs, supply sustainability, GMP and EHS system.

On March 2, 2022, Xlement, invested and incubated by Viva BioInnovator, received the notice of passing the performance evaluation from the Ministry of Science and Technology of the People´s Republic of China. Its project "R&D and Mass Production of NanoSPR COVID-19 Particle Test Kit" is one of the key projects of the "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" program, which serves an essential part to key COVID-19-related scientific research ongoing in China. In addition, Xlement's COVID-19 Test Kit has also been certified by the European Union CE for future massive production and will be put into use soon.

XLEMENT

Viva Biotech Launched New Official Website and LOGO

In 2021, Viva Biotech not only completed the layout expansion from the CRO service of drug R&D to the production, but also upgraded its official website and logo. This revision of the official website presents the corporate vision, mission and values of Viva Biotech with a new look, as well as of Viva Biotech' service layout and core technology more comprehensively. In addition, the Company also upgraded the visual identity of the logo of Viva BioInnovator (VBI).



VIVA Linkedin

Research & Development Progress

QureBio's First Bispecific Antibody Q-1802 Combination Clinical Trial (phase I/II) Was Approved

On April 12, 2022, QureBio announced that its self-developed bispecific antibody Q-1802 was approved by National Medical Products Administration for the phase I / II clinical trial of preliminary efficacy, safety and tolerance of combined standard treatment regimen in patients with gastrointestinal tumors. Previously, the IND application of Q-1802 has been successfully approved in both China and the United States, and the Phase I clinical study of single drug safety and efficacy has been successfully advanced. Partial Phase I safety study results will be presented at ASCO meeting in June 2022.

QureBio's Phase II Clinical Trial Application of Q-1802 has been accepted by CDE

On January 26, 2022, QureBio announced that its Phase II clinical trial application of Q-1802 for GI tract multi-tumor Indications has been formally accepted by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA). Q-1802 is the first CLDN18.2/PD-L1 dual antibody to reach human trial in the world.

Research & Development Progress

VivaVision Announced Positive Topline Results of VVN001 in the Phase II Clinical Study for the Treatment of Dry Eye Disease

On March 23, 2022, VivaVision announced positive topline results from a Phase II clinical study of VVN001 in patients with dry eye disease. In total corneal staining of the trial, the VVN001 treatment groups were clinically significant and statistically significant and showed a dose and treatment duration-related improvement relative. In terms of safety, no significant treatment-related safety findings were observed during the study, indicating that VVN001 was safe and well-tolerated.

VivaVision Announced the Establishment of Scientific Advisory Board and the First Patient Enrollment in Phase II Clinical Trials of VVN001 in China

In December 2021, VivaVision announced the establishment of Scientific Advisory Board (SAB), and the first SAB meeting was successfully held. The SAB aims to provide in-depth suggestions for the continuous development of innovative ophthalmic drugs. Additionally, VivaVision announced that the company had completed the first patient enrollment and dose in phase II clinical trials in China of LFA1 Inhibitor VVN001, a novel drug for dry eye disease treatment independently developed by VivaVision.

Investment Progress

Apeiron Completed US$17.5 Million Series A Financing and Launched Strategic Partnerships with Viva Biotech

On March 30, 2022, Apeiron announced it has completed a US$17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and other existing investors. This is Apeiron's second round of financing following a Pre-A+ round in May 2021. The investment will enable the company to advance its lead CDK7 program to enter clinical trials, as well as several earlier-stage programs. Apeiron also announced a strategic partnership with Viva Biotech under which Viva Biotech provides world-leading structure-based drug discovery expertise to enhance Apeiron's AI-empowered innovative drug discovery.

Triumvira Completed Extension of Series A Financing, for Total Round of Approximately US$100 Million

On March 17, 2022, Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. This round was led by B Capital Group, with participation from ATEM Capital and others, joined by significant participation from existing investors, Leaps by Bayer and Northpond Ventures. The financing proceeds will support the continued preclinical and clinical development of Triumvira's T cell Antigen Coupler (TAC)-T cell therapy programs.

Investment Progress

ArrePath Announced US$20 Million Seed Financing

On March 3, 2022, ArrePath, an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, announced that it has raised $20 million in seed financing. The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator and others. The proceeds will be used to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).

Meanwhile, ArrePath also announced that Dr. Lloyd Payne has been named President and CEO. Dr. Payne has more than 25 years of scientific and business leadership in the discovery and development of anti-infectives.

Announced the Completion of Tens-of-Millions-of-Dollars Series A Financing

On February 18, 2022, Xlement announced the completion of tens-of-millions-of-dollars Series A financing. Volcanics Venture and Neovision Capital co-led the investment. After this round of financing, Xlement will continue to optimize its proprietary technologies such as digital NanoSPR imaging microfluidic chip and NanoSPR nucleic acid amplification assay chip to further improve the throughput and sensitivity of the testing and realize the clinical and POCT diagnosis of autoimmune diseases, cancer, and infectious diseases by high-throughput multiplex immunoassay products and rapid multiplex nucleic acid testing products based on NanoSPR chips.

HAYA Completed US$5 Million Seed Extension Led by Humboldt Fund and Establishes U.S. Location

On February 9, 2022, HAYA Therapeutics announced that it has successfully closed a US$5 million seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA, with participation from existing investors including Viva BioInnovator. This round of financing brings the total amount raised for the seed round to approximately US$25 million. In addition, HAYA has established a new laboratory space at JLABS @ San Diego.

ABM Therapeutics Completed US$30 Million Series B Financing

On January 4, 2022, ABM Therapeutics, a biopharmaceutical company that focuses on small molecule research and development of novel drugs for the treatment of brain cancers, announced the completion of a US$30 Million Series B financing. Photon Fund and HighLight Capital led the round. The funds will be used to accelerate the clinical research of ABM-1310 in China and the U.S., develop several existing preclinical projects, build the company's pipeline and the management team, and improve the innovative brain medicine R&D platform.

Investment Progress

QureBio Completed Nearly RMB200 Million in Series B Financing

December 2021, QureBio, a biotech company that dedicated to the development of innovative antibody drugs, announced it has completed nearly RMB200 Million in Series B Financing. The round was led by BOCOM International Holdings. Other investors who joined the round include Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.

Business Progress

Dr. Kasper Roet, CEO of QurAlis, Won a Prize in the 2022 Henri Termeer Award

On April 12, 2022, The Termeer Foundation announced that Dr. Kasper Roet, co-founder and CEO of QurAlis, a bio-innovation company, has received the 2022 Henri Termeer Transalantic Connections Award. Dr. Kasper Roet made remarkable contribution in promoting the establishment of Life Sciences Partnership between Massachusetts and the Netherlands.

AIxplorerBio and AliveX, BIOCAST Reached a Strategic Collaboration Agreement, To Jointly Promote the Development of Precision Medicines of IBD

On December 23, 2021, AIxplorerBio, invested and incubated by Viva BioInnovator, announced the signing of a strategic collaboration with AliveX and BioCasting (both invested and incubated by Viva BioInnovator) to promote the development of precision medicines of Inflammatory Bowel Disease (IBD). The collaboration integrates the strengths of the three companies to jointly promote the development of precision medicines of IBD, preclinical studies, and IND enabling in China and the U.S.

About Viva Biotech

Listing Date
2019.05.09
Price (2022.05.20)
HKD 2.36
52 WK Range
HKD 2.06 - 11.64
Market Cap (2022.05.20)
HKD 4.57B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, etc.. Our business covers all aspects of therapeutic strategies and drug modalities including small molecules and biologics across the pharma and biotech spectrum. Through our subsidiary Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners One-Stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. In addition, Viva has embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2021, Viva Biotech has provided drug R&D and production services to 1,820 biotech and pharmaceutical clients around the world. We have invested and incubated 87 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva's platform.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com